海尔生物(688139.SH)2025年度归母净利润2.5亿元，下滑31.6%

Core Viewpoint - Haier Biomedical (688139.SH) reported its 2025 performance, showing a slight increase in revenue but a significant decline in net profit [1] Group 1: Financial Performance - The company achieved operating revenue of 2.33 billion yuan, representing a year-on-year growth of 2.0% [1] - The net profit attributable to shareholders was 250 million yuan, reflecting a year-on-year decrease of 31.6% [1] Group 2: Revenue Breakdown - Overseas revenue reached 840 million yuan, marking a year-on-year increase of 17.9%, accounting for a record high of 36% of total revenue, up 5 percentage points from 2024 [1] - Revenue from the European region grew by 16.0%, the Asia-Pacific region by 26.0%, the Americas by 12.2%, and Africa by 17.8% [1] - Domestic revenue was 1.47 billion yuan, showing a year-on-year decline of 5.5% [1] Group 3: Industry Segmentation - New industry revenue accounted for 48.5% of total revenue, with a year-on-year growth rate of 8.8% [1] - Low-temperature storage industry revenue made up 51.5% of total revenue, experiencing a year-on-year decline of 3.9% [1] - Following a positive growth in the third quarter, the fourth quarter showed accelerated growth, indicating a gradual recovery from the bottom [1]